25th Oct 2007 07:01
International Medical Devices PLC25 October 2007 25 October 2007 International Medical Devices plc (AIM: INT) ("IMD" or "the Company") Results for the year ended 31 August 2007 International Medical Devices plc announces its financial results for the yearended 31 August 2007. Highlights • Turnover up 195% to £11.2 million from £3.8 million • Profit after tax of £538,000 (from a loss of £360,000 in 2006) • Gross profit margin up to 41% from 36% (2006) • Acquisitions of two companies adding to a growing portfolio • Renewal of existing distribution agreements, and new distribution agreements signed • Three companies integrated into one operation located in Selby, Yorkshire Acquisitions The two acquisitions that IMD made during the 2006 financial year were asfollows: Pro-Care, which was acquired for £4 million and £760,000 for MinsterMedical Ltd, and since the acquisitions both purchases have strengthened theAcute Care Division, although these results only include 8 months' trading forboth Companies. These two acquisitions were funded through the provision of a term loan of £3.95million from Allied Irish Bank Plc and a flexible book debt facility of which£1.59 million has been utilised, which allowed the Company to refinance allexisting Group debt. Integration As part of the Company's focus on organic growth and to be in a position toacquire new businesses, the Board has appointed Bill McGrath as a ConsultantChief Operating Officer to oversee the integration of the operating divisions. Akey challenge for IMD over the past six months and during the next year is tocontinue to integrate the acquired businesses into one coherent businessoperation under the IMD corporate brand albeit organised on a divisional basis.Bill has a proven track record in successfully integrating diverse operatingcompanies and is now responsible for putting in place a sustainable integrationand operations plan for the five business. Lindsay Sanford, Chairman of IMD, commented: "The Board of IMD is delighted with these results and the acquisitions it hasmade during the year. The medical device sector is a fast growing one and webelieve that IMD is well placed to act as a consolidator in this market place." Copies of the accounts have been sent to shareholders today, and will beavailable to download from the Company's website shortly. The Annual General Meeting will be held on 11 December 2007 at the offices ofJMFinn Capital Markets Limited, 4 Coleman Street, London EC2R 5TA. Full Directors' reports and financials follow. For further information, contact: International Medical Devices JMFinn Capital Markets Parkgreen CommunicationsChris Thomas, CEO Geoff Nash Simon Robinson+44 203 008 4960 +44 20 7600 1658 Erica Nelson +44 207 851 7480 CHAIRMAN'S STATEMENT I am pleased to announce your Company has successfully continued its growthstrategy of 'buy and build' over the past 12 months. This strategy has delivereda 195% increase in Revenue to £11.2million with Operating Profit of £902,000 anda Profit after Tax of £538,000 compared to the 2006 Loss of £360,000. In this period your Company added two further acquisitions to a growingportfolio of medical products, creating a profitable Medical Device tradinghouse. As I outlined in the interim report, this strategy is proof that IMDcontinues to establish itself within the healthcare market in supplying both newand established brands into the medical devices sector. Acquisitions IMD has made two acquisitions during the period. The purchase price was £4million for Pro-Care Limited and £760,000 for Minster Medical Ltd, and since theacquisitions both purchases have strengthened The Acute Care Division, althoughthese results only include 8 months trading. These two acquisitions were funded through the provision of a term loan of £3.95million from Allied Irish Bank Plc and a flexible book debt facility of which£1.59 million has been utilised, which allowed us to refinance all existinggroup debt. Integration As part of our focus on organic growth and to be in a position to take on newbusiness from acquisition, the Board appointed Bill McGrath as a ConsultantChief Operating Officer to oversee the integration of the operating divisions. A key challenge for IMD over the past six months and during the next year is tocontinue to integrate the acquired businesses into one coherent businessoperation under the IMD corporate brand albeit organised on a divisional basis. Bill has a proven track record in successfully integrating diverse operatingcompanies and is now responsible for putting in place a sustainable integrationand operations plan for the five businesses acquired to date. Divisional structure After careful consideration and to achieve further operational savings, IMD nowintends to focus on three operating divisions rather than as previouslyreported. - Acute Care- Aged Care- Devices IMD will continue to target the NHS and private health sector with its productportfolio where essential spending is required to provide medical services whichwill not be affected by the economic climate. New Products IMD has launched a number of new products ranging from wound drains torespiratory systems such as CPAP. In particular the Aged Care Division workedclosely with Inogen Inc to launch their oxygen concentrator, a lightweight, portable system with unique features. Brand Awareness IMD has developed two new brands to be launched in the next twelve months.Firstly the "Surety" brand for a range of high quality safety devices. Secondly,the "Integrity" Brand for value for money consumables. To successfully grow and secure IMD's place as a major distributor in the healthcare market, it is essential we develop a portfolio of products under IMD's ownbrand names. This will help deliver sustainable margins and build market share,thereby adding future asset value to the company. Safe Needle Progress/Launch of "Surety" brand In the past 12 months, IMD has made considerable progress in the development ofits safe needle patent. Having obtained a CE marking certificate for the safeneedle, IMD has continued the evaluation process agreed with the NHS. Currently the Surety Needle is being evaluated by the South West AmbulanceService NHS Trust and at Papworth Hospital. IMD will formally launch its SuretyNeedle at the Dusseldorf Medica exhibition in November, and this will be thefirst product under the "Surety" brand. Previously this product was referred toas "Clip-On", and formed part of the intellectual property acquisition by IMD inJuly 2005. It is our intention to launch other complimentary safety intravenousinjection and phlebotomy devices under this brand over the next 18 months. Buy and Build Strategy The past six months have seen the company focus on integration, cost reductionand the refocusing of the Devices Division. The group continues to seek furthergrowth opportunities, and is working with various financial institutions who arekeen to fund us to achieve our growth ambitions, and currently we haveidentified a number of targets for acquisition. Non-Executive Directors During the year Doug Sims and Don O'Sullivan, the representatives of EastlandMedical Systems Limited (EMS) on the IMD Board, stepped down following thedisposal in December 2006 of EMS's entire holding of 40.5 million shares in IMD. This disposal has paved the way for each company to establish its own identityin the global health care market. The business relationship will continue andboth companies intend to collaborate on existing projects and explore futureopportunities. We thank Doug and Don for their valuable contribution. Conclusion IMD continues to deliver its original strategy of building a healthcare groupwith sustainable revenues and profit growth. The success of our business strategy is reflected in our Annual Report, whereIMD has delivered a significant Operating Profit of £902,000 on Revenue of £11.2million. We are confident that, by combining a focused integration plan with an ongoingbuy and build strategy, IMD can continue to grow organic sales and complete newacquisitions. On behalf of the board I would like to thank the Executive Team and staff fortheir contribution and hard work over the past 12 months which is alwaysappreciated. L.C.S. SanfordChairmanOctober 2007 CHIEF EXECUTIVE'S REPORT In the calendar year 2006, IMD acquired four companies. This momentum isreflected in IMD's quick progress in achieving profitability in the year to the31st August 2007. However, the last six months has seen a period where the focushas been on integration, cost reduction, stock management, sales forcerationalisation and margin management. Integration To date IMD has acquired five companies. Following the acquisition of Pro-CareLtd and Minster Medical Ltd in December 2006, it was decided to integrate thesetwo businesses with Meddis Ltd which had been acquired in September 2005. Thesethree businesses now constitute the Acute Care Division based in Selby, NorthYorkshire. All warehousing, accounting and sales management have beencentralised in Selby, and the Division is now operated under two distinctbusiness units (Enteral and Surgical) and sales teams managed by the salesdirector, John Tharme. As outlined in the Divisional review, the productportfolio has been rationalised and refocused to meet specific hospital needs.Certain lines have been culled, like ophthalmic scalpels which on analysis weremaking a negative contribution. The main challenge for the next two years is to refocus the Devices Division.The Division is in the process of changing its sales mix away from a dependencyon hardware sales to a more regularised order flow of consumable and disposablemedical devices like the Penfine diabetic needle and safe retractable needle, 'Surety'. The Division's sales force had for many years sold GE Healthcare ECGmachines, now replaced by Welch Allyn in the product portfolio. The installedbase of such machines is finite within the NHS PCT and Hospital Trust framework.IMD has assembled its own proprietary branded portfolio ('Integrity') of ECG 'consumables', and in coming months will be in a position to offer our customerlower prices. Brands IMD has assembled an impressive range of brands that are sold into the NHS andoverseas markets. The IMD business model is based both on acquisitions andexploitation of our IP. Brands which are represented by IMD through contractualdistribution agreements include: Ypsomed (diabetic needles : "Penfine"), WelchAllyn (ECG's and defibrillators), SunTech Medical (blood pressure monitors),Respironics (CPAP), Inogen (oxygen concentrator), Applied Medical Technologies(mini button enteral feeding device), Serres (disposable suction liners) andSaterlabs (Oxygen catheters). Typically IMD have two to three years exclusiveagreements with these principals, and to balance these distribution agreements,IMD also invests in its own brands, obtained either via acquisition or throughexploitation of our own technology. These brands include Tendertip and Caretip(open and closed suction catheters), Kylie, Kanga and Martex (continence careproducts), Breeze (tracheotomy and endotracheal Care), Intex (selfcatheterisation), Cherishh (SCP Clamps, eyeshields and bonnets for neo-natalcare) and Tubicare (medical tubing, catheters and naso-gastric bile bags). Over the next 12 months IMD will launch two new brands into the medical devicesmarket. "Surety" is the brand under which the retractable safe needle is to belaunched, with all products in the Surety portfolio united by their focus on safety and smart design. Each has been designed to be intuitive and to reduce risk to both healthcare professionals and patients. The Surety needle is scheduled to be launched at Medica, the 19th World Forumfor Medicine in Dusseldorf, Germany on November 14-17, 2007. The intention is toextend the brand range to include blood collection needles, blood collectiontube holders, hypodermic needles, butterfly needles and cannula. Within the next18 months, this will allow IMD sales force to offer a range of Surety products,and will provide a stream of fresh, new products with added features atcompetitive prices. The second new brand to be introduced to market is the "Integrity" range ofcardiology consumables that will include defibrillator pads, cuffs, lead wires,gels and pulse oximetry probes. The strategic importance of a medical device distribution business like IMDpossessing a balanced portfolio of 3rd party brands and in-house brands has beenconfirmed by the recent privatisation of NHS Logistics and the Purchasing andSupply Agency (PASA). In October 2006, the government awarded a 10 yearoutsourcing contract to DHL under which DHL became responsible for procuring arange of products - from catering suppliers to medical equipment - anddelivering them to NHS hospitals and GP surgeries. From October 2006, the newservice has been known as NHS Supply Chain and remains managed by the NHSBusiness Service Authority. NHS Supply Chain and IMD DHL operates NHS Supply Chain as the agent of the NHS BSA with the contractcovering the supply and delivery of 10 product categories. Of relevance to IMD,these categories include medical supplies, bedding and linen, dressings, patientappliances and lab equipment. Over the 10 categories, the NHS uses around500,000 different products with a value of £3.7 billion per year. NHS Supply Chain lists all product categories open to supplier bids, andoperates a centralised procurement system that offers new opportunities tosuppliers like IMD to grow market share through their ability to leveragecustomer purchasing volume. The opportunity for IMD to sell its brands to the NHS is in a consultativeapproach to supplying NHS Trusts via the NHS Supply Chain who themselvesgenerate margins and operate a sales force of 64 representatives nationally,plus 20 account managers. Through our 'buy and build' approach, IMD has acted asa mini-consolidator in the market, and has the ability to sell into the NHS on anational as opposed to a fragmented regional scale. IMD enjoys a strong relationship with NHS Supply Chain with over 50% of theAcute Care Division sales via this distribution channel. The Age Care Divisionwas successful in securing a 3 year national NHS contract for direct patientdelivery with the three continence care brands, Kylie, Kanga and Martex. IMD hasongoing tenders and supply agreements in place, and has recently receivedplaudits for high levels of service. Summary The challenge for IMD is to consolidate the businesses acquired to date into acoherent sustainable business that will deliver increasing revenue and profitvia efficient integration practices and cost management, and by continuing tolaunch innovative new products to provide sales growth. This, combined with our 'buy and build' strategy should provide the growthstrategy to generate more sales and shareholder value. This is the focus for IMDover the next 12 months. Christopher ThomasChief Executive Officer 19 October 2007 FINANCIAL REVIEW I am pleased to report the financial performance of IMD during the period.Revenues increased to £11,247,000 from £3,817,000 in 2006, Operating Profit of£902,000 compares with a Loss of £(222,000) in 2006, and Profit after Taxamounted to £538,000 compared with a Loss of £(360,000) to 31 August 2006. Two further companies were acquired in December 2006, both contributing towardsthe consolidated results from that date. Following these acquisitions, the dayto day operations and administration of these businesses were merged, togetherwith our subsidiary Meddis Limited. All are now based in Selby, Yorkshire.This integration was very successfully and speedily implemented, operationally,logistically, and from the IT perspective. Fund Raising and Acquisitions Fund raising undertaken in July 2007 amounted to £515,300 before costs. Thesefunds were raised to allow IMD to continue with its organic growth. IMD acquired two further companies in December 2006, being Pro-Care Limited andMinster Medical Limited. The acquisition of these companies was financedthrough bank debt. Consideration was structured in the form of cash, IMDshares, and deferred consideration. The deferred consideration is performancerelated, and could amount to additional payments in the form of shares of£1,240,000 over a period of three years to 31 August 2010, based on the shareprice when payment falls due. Capital reserves include expected future deferred consideration payable in theform of shares, amounting to £3,130,000, in accordance with InternationalFinancial Reporting Standard 3. Revenue and Gross Margin IMD achieved Revenues of £11.2 million during the year to 31 August 2007. Thiscompared with Revenues of £3.8 million to 31 August 2006. Revenues incorporatepost acquisition trading results, and therefore include the 3 previousacquisitions for the full year, together with Pro-Care Limited and MinsterMedical Limited for the period from 21 December 2006. A full review of all product lines was undertaken during the period, resultingin rationalisation of those lines where profit generated from the sales effortwas not commensurate with the rewards achieved. This has resulted in lowerRevenue in the short term, but has allowed margin improvement, and will in turnimprove profitability in future periods. Revenue has also been affected bylower capital equipment sales during the period, but these have been compensatedby excellent performances elsewhere in the group. All subsidiaries madecontributions to profit in the period, and there are many more organic andacquisition opportunities available in each division. Gross margin on Revenues averaged 41% for the year, up from 36% in 2006. Thisincrease is a reflection of product mix between the different operatingdivisions, and in part the cutting of certain product lines noted above. Whereproduct lines were rationalised, it is for the long term benefit of the Group'sprofitability. As a result, while all potential cost savings will not have beenreflected in the 2007 Profit & Loss account, benefits have already been seen inmargin improvement. Operating Cash flows IMD produced positive Operating Cash flows before movements in working capitalof £1,014,000 in the period to 31 August 2007 (2006: Outflow £262,000). Operating Profit, Interest, and Taxation IMD achieved an Operating Profit for the year, amounting to £902,000 (2005: Loss£222,000). As noted with Revenues, this reflects contribution from Pro-CareLimited and Minster Medical Limited for a period of eight months, postacquisition. With interest rates having increased significantly over the last twelve months,together with increased borrowings, this has resulted in higher interest chargesfor the period. IMD entered into an interest cap agreement, which caps theinterest base rate at 6%, before borrowing margin, for borrowings of £3 millionfor a period of 2 years from March 2007. There is no charge to Corporation Tax, as Group tax losses available have beenoffset against current year profits, subject to HM Revenue and Customsagreement. Earnings Per Share Basic Earnings Per Share (EPS) are 0.20 pence per share (2006: Loss per share0.21 pence). Fully diluted, EPS is 0.17 pence (2006: Loss per share 0.21pence). Cash and Net Debt The Board determined to finance the two acquisitions made in December 2006 byincreasing IMD's borrowings. As a result, a cashflow term loan of £3,955,000was entered into, together with an invoice discounting facility. These fundswere used to make the acquisitions, together with repayment of existing debtinherited with the acquisition of RME Holdings Limited, its subsidiary ResponseMedical Equipment Limited, and EMS Medical Limited. The Group had cash of £463,000 at the year end (2005: £706,000). This is beforebank debt of £800,000 repayable within one year, and bank debt of £3,155,000repayable after more than one year. In addition, IMD operates an invoicediscounting facility which was utilised to a level of £1,594,000 at 31 August2007 (2006: £212,000). Therefore net debt amounted to £5,021,000 (2006:£1,023,000). Gearing, net of cash balances, is 17.4% of Total Equity andLiabilities (2006: 4.8%). Net finance cost for the period amounted to £364,000(2006: £53,000). Working Capital The business relies on having inventory available immediately, due to therequirements of its customers. Inventories at 31 August 2007 amounted to£2,471,000 (2006: £1,791,000), the increase reflecting the two acquisitions madeduring the period. Goodwill IMD has Goodwill on the Balance Sheet amounting to £14,165,000 (2006£8,674,000), representing purchased Goodwill. This Goodwill arises directlyfrom the difference between the consideration paid for the acquisition of thesubsidiaries, and the net assets of those subsidiaries at the time ofacquisition. Goodwill includes expected future deferred consideration payablein the form of shares, in accordance with International Financial ReportingStandard 3. International Financial Reporting Standards IMD has adopted International Financial Reporting Standards for its AnnualReport and Accounts to 31 August 2007, as it did for the Annual Report andAccounts to 31 August 2006. The information is therefore comparable, with noadjustments being necessary. Dividends IMD is not declaring a dividend for the year. In the Interim Report to 28February 2007, the Chairman indicated a desire to commence paying dividends withrespect to the financial year ending 31 August 2008, and this will be consideredby the Board of Directors at the appropriate time. Taxation There is no corporation tax charge for the year. Tax losses available in thegroup, are being used to offset taxable profits in the period, subject to HMRevenue & Customs agreement (2006: £Nil). M P AchesonFinance Director 19 October 2007 CONSOLIDATED INCOME STATEMENT FOR THE PERIOD ENDED 31 AUGUST 2007 Group Notes Year ended Year ended 31-Aug-07 31-Aug-06 £'000 £'000 Revenue 2 11,247 3,817Cost of sales (6,564) (2,443) Gross profit 4,683 1,374 Distribution expenses (1,820) (460)Administration expenses (1,961) (1,136) Operating Profit / (Loss) before exceptional 902 (222)items Restructure costs - (85) Operating Profit / (Loss) 3 902 (307) Finance costs (384) (70)Finance income 20 17 Profit / (Loss) before tax 538 (360)Taxation 4 - - Profit for the year 538 (360) Profit / (Loss) per shareBasic 5 £0.0020 £(0.0021) Diluted 5 £0.0017 £(0.0021) There were no other gains or losses other than those recognised in the incomestatement. All activities relate to contributing activities. The notes following these tables form part of these financial statements. STATEMENTS OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 AUGUST 2007 Group Share Share Capital Retained Total Capital Premium Reserve Earnings £'000 £'000 £ '000 £'000 £'000 Balance as at 1 September 2006 2,489 12,499 1,350 (677) 15,661 Changes in equity for the yearto 31 August 2007: Profit for the year - - - 538 538 Total recognised income and - - - 538 538expense for the year Issue of share capital 471 1,379 - - 1,850Issue costs - (170) - - (170)Deferred contingent - - 1,780 - 1,780consideration Movement in year 471 1,209 1,780 538 3,998 Balance as at 31 August 2007 2,960 13,708 3,130 (139) 19,659 Company Share Share Capital Retained Total Capital Premium Reserve Earnings £'000 £'000 £'000 £'000 £'000 Balance as at 1 September 2006 2,489 12,499 1,350 (862) 15,476 Changes in equity for the yearto 31 August 2007:Profit for the year - - - 435 435 Total recognised income and - - - 435 435expense for the year Issue of share capital 471 1,379 - - 1,850Issue costs - (170) - - (170)Deferred contingent - - 1,780 - 1,780consideration Movement in year 471 1,209 1,780 435 3,895 Balance as at 31 August 2007 2,960 13,708 3,130 (427) 19,371 BALANCE SHEET AS AT 31 AUGUST 2007 Group Company 2007 2006 2007 2006 £'000 £'000 £'000 £'000AssetsNon-current assetsGoodwill 14,165 8,674 - -Other Intangible Assets 9,078 8,479 8,636 8,001Property, plant and equipment 311 233 30 -Investments in subsidiaries - - 14,107 8,494 23,554 17,386 22,773 16,495 Current AssetsInventories 2,471 1,719 - -Trade receivables 2,055 1,276 - -Other receivables 364 290 152 -Intercompany loan - - 442 188Cash and cash equivalents 463 706 468 175 5,353 3,991 1,062 363 Total assets 28,907 21,377 23,835 16,858 Equity and liabilitiesEquity attributable to equityholders of the parentShare capital 2,960 2,489 2,960 2,489Share premium 13,708 12,499 13,708 12,499Capital reserves 3,130 1,350 3,130 1,350Retained earnings (139) (677) (427) (862) 19,659 15,661 19,371 15,476Non-current liabilitiesBank loans 3,155 1,300 3,155 -Convertible loan notes - 250 - 250Other non-current liabilities 148 444 - - 3,303 1,994 3,155 250Current liabilitiesTrade and other payables 5,145 3,122 509 349Intercompany loan - - - 533Convertible loan notes - 250 - 250Bank loans 800 350 800 - 5,945 3,722 1,309 1,132 Total liabilities 9,248 5,716 4,464 1,382 Total equity and liabilities 28,907 21,377 23,835 16,858 L.C.S. Sanford, Chairman 19 October 2007 CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 AUGUST 2007 Year Ending Year Ending Group Company 31-Aug-07 31-Aug-06 31-Aug-07 31-Aug-06 £'000 £'000 £'000 £'000Cash flows from operating activitiesProfit /(Loss) from operations 902 (307) 661 (554) Adjustments for:Depreciation of property, plant and equipment 104 45 2 -Share Options Expense 8 - 8 - Operating cash flows before movement in working capital 1,014 (262) 671 (554) (Increase) in inventories (16) (316) - -(Increase) / Decrease in receivables (588) 892 (1,041) (105)Increase / (Decrease) in payables 460 (320) (578) 325Tax paid (394) (80) - -Cash generated from operations 476 (86) (948) (334) Interest paid (384) (70) (288) - Net cash from/(used in) operating activities 92 (156) (1,236) (334) Cash flows from investing activitiesInterest received 20 17 6 8Acquisition of Trading Subsidiary net of cash acquired (2,585) (2,434) - -Investment in Trading Subsidiary - - (2,867) (2,633)Acquisition of Non Current Assets (552) (44) (32) (44)Proceeds From Disposal of Non Current Assets 10 - - - Net cash (used in) investment activities (3,107) (2,461) (2,893) (2,669) Cash flows from financing activitiesNet proceeds on issues of shares 467 2,815 467 2,815Net borrowings 2,305 145 3,955 -Net cash from financing activities 2,772 2,960 4,422 2,815Net increase in cash and cash equivalents (243) 343 293 (188) Cash and cash equivalents at beginning of period 706 363 175 363 Cash and cash equivalents at end of year 463 706 468 175 Bank balances and cash 463 706 468 175 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2007 1. Presentation of Financial Statements The financial statements have been prepared in accordance with InternationalFinancial Reporting Standards ("IFRS") and with those parts of the Companies Act1985, applicable to companies reporting under IFRS. The financial reports havebeen prepared under the historical cost convention. The preparation of financial statements in conformity with generally acceptedaccounting principles requires the use of estimates and assumptions that affectthe reported amounts of assets and liabilities at the date of the financialstatements and the reported amounts of revenues and expenses during thereporting period. Although these estimates are based on management's bestknowledge of the amount, event or actions, actual results ultimately may differfrom those estimates. A summary of the more important accounting policies, whichhave been applied consistently, is set out below:- 1.1 Basis of Accounting The financial statements are prepared in accordance with the historicalcost convention. 1.2 Basis of consolidation The consolidated financial statements incorporate the financial statements ofthe Company and enterprises controlled by the Company (and its subsidiaries) andare made up to 31 August each year. Control is achieved where the Company hasthe power to govern the financial and operating policies of an investeeenterprise so as to obtain benefits from its activities. The financial statements of International Medical Devices Plc have been preparedin accordance with the International Financial Reporting Standards ("IFRS").Where necessary, adjustments are made to the financial statements ofsubsidiaries to bring the accounting policies used into line with those used byother members of the Group. All significant intercompany transactions and balances between Group enterprisesare eliminated on consolidation. The principal subsidiary undertakings at 31 August 2007 are as follows: Company Activity % Ownership Meddis Ltd Medical Distribution 100Response Medical Equipment Ltd Medical Distribution 100RME Holdings Ltd Dormant Company 100EMS Medical Ltd Medical Distribution 100Procare Ltd Medical Distribution 100Minster Medical Ltd Medical Distribution 100Global Medical Devices Ltd Dormant Company 100 All companies are incorporated and registered in England. 1.3 Revenue recognition Revenue represents the total invoice value, excluding value added tax, of salesmade in the year. Interest income is accrued on a time basis, by reference tothe principal outstanding and at the interest rate applicable. Dividend incomefrom investments is recognised when the shareholders' rights to receive paymenthave been established. 1.4 Foreign currencies Transactions in foreign currency are translated at the foreign exchange rateruling at the date of the transaction. Monetary assets and liabilitiesdenominated in foreign currencies at the balance sheet date are translated tosterling at the foreign exchange rate ruling at that date. Foreign exchangedifferences arising on translation are recognised in the income statement.Non-monetary assets and liabilities that are measured in terms of the historicalcost in a foreign currency are translated using the exchange rate at the date ofthe transaction. Non-monetary assets and liabilities denominated in foreigncurrencies that are stated at fair value are translated to sterling at theforeign exchange rates ruling at the dates that fair value was determined. 1.5 Inventory Inventory is valued to the lower of cost and net realisable value. 1.6 Intangible assets Goodwill All business combinations are accounted for by applying the purchasemethod. Goodwill represents the amount arising on acquisition of subsidiaries.In respect of business acquisitions, goodwill represents the difference betweenthe cost of the acquisition and the fair value of the net identifiable assetsacquired. Goodwill is stated at cost less any accumulated impairment losses.Goodwill is allocated to cash-generating units and is no longer amortised but istested annually for impairment (see accounting policy 1.8). Negative goodwill arising on acquisition is recognised directly in theincome statement. 1.7 Property, plant and equipment Fixtures and equipment are stated at cost less accumulated depreciation. Depreciation is charged so as to write off the cost or valuation or assets overtheir estimated useful lives, using the straight-line method, on the followingbases. Fixtures, Fittings and equipment 20%Motor Vehicles 25%Plant and Machinery 10%Leasehold Property Improvements straight line over life of lease The asset's residual values and useful lives are reviewed, and adjusted ifappropriate, at each balance sheet date. An asset's carrying amount is writtendown immediately to its recoverable amount if the asset's carrying amount isgreat than its estimated recoverable amount. Gains and losses on disposals are determined by comparing the disposal proceedswith the carrying amount and are included in the income statement. 1.8 Impairment The carrying amounts of the Group's assets, other than deferred tax assets (seeaccounting policy 7), are reviewed at each balance sheet date to determinewhether there is any indication of impairment. If any such indication exists,the asset's recoverable amount is estimated. For goodwill, assets have an indefinite useful life and intangible assets thatare not yet available for use, the recoverable amount is estimated at eachbalance sheet date. An impairment loss is recognised whenever the carrying amount of an asset or itscash-generating unit exceeds its recoverable amount. Impairment losses arerecognised in the income statement. Impairment losses recognised in respect of cash-generating units are allocatedfirst to reduce the carrying amount of any goodwill allocated to cash-generatingunits (group of units) and then, to reduce the carrying amount of other assetsin the unit (group of units) on a pro rata basis. The recoverable amount of the Group's receivables carried at amortised cost iscalculated as the present value of the estimated future cash flows, discountedat the original effective interest rate. Receivables with a short duration arenot discounted. The recoverable amount of other assets is the greater of their net selling priceand the value in use. In assessing value in use, the estimated future cash flowsare discounted to their present value using a pre-tax discount rate thatreflects current market assessments of the time value of money and the risksspecific to the asset. For an asset that does not generate largely independentcash inflows, the recoverable amount is determined for the cash-generating unitto which the asset belongs. An impairment loss in respect of a receivable carried at amortised cost isreversed if the subsequent increase in recoverable amount can be relatedobjectively to an event occurring after the impairment loss was recognised. An impairment loss in respect of goodwill is not reversed. In respect of other assets, an impairment loss is reversed if there has been achange in the estimates used to determine the recoverable amount. An impairment loss is only reversed to the extent that the asset's carryingamount does not exceed the carrying amount that would have been determined, netof depreciation or amortisation, if no impairment loss as been recognised. 1.9 Trade receivables Trade receivables are recognised initially at fair value less provision forimpairment. A provision for impairment of trade receivables is established whenthere is objective evidence that the Group will not be able to collect allamounts due according to the original terms of receivables. The amount of theprovision is the difference between the asset's carrying amount and the presentvalue of estimated future cash flows, discounted at the effective interest rate.The amount of the provision is recognised in the income statement. 1.10 Trade payables Trade payables are stated at their nominal value. 1.12 Financial Risk Management The Group uses a limited number of financial instruments, comprising cash,short-term deposits, bank loans and overdrafts and various items such as tradereceivables and payables, which arise directly from operations. The Group doesnot trade in financial instruments. Financial risk factors The Group's activities expose it to a variety of financial risks: market risk(including currency risk and interest rate risk), credit risk, liquidity riskand cash flow interest rate risk. The Group's overall risk managementprogramme focuses on the unpredictability of financial markets and seeks tominimise potential adverse effects on the Group's financial performance. Market risk a) Foreign exchange risk The Group operates internationally and is exposed to foreign exchange riskarising from various currency exposures, primarily with respect to the UK poundand Euro. Foreign exchange risk arises from future commercial transactions. b) Credit risk The Group has no significant concentrations of credit risk and has policies inplace to ensure that sales are made to customers with an appropriate credithistory. c) Liquidity risk Prudent liquidity risk management implies maintaining sufficient cash andavailable funding through an adequate amount of committed credit facilities. TheGroup ensures it has adequate cover through the availability of bank overdraftand loan facilities. d) Cash flow and interest rate risk The Group finances its operations through a mix of cash flow from currentoperations together with cash on deposit and bank and other borrowings.Borrowings are generally at floating rates of interest and no use of interestrate swaps has been made. e) Fair value estimation The nominal value less impairment provision of trade receivables and payablesare assumed to approximate their fair values. The fair value of financialliabilities for disclosure purposes is estimated by discounting the futurecontractual cash flows at the current market interest rate that is available tothe Group for similar financial instruments. 1.13 Deferred Tax Deferred tax is provided in full, using the liability method, on temporarydifferences arising between the tax bases of assets and liabilities and theircarrying amounts in the consolidated financial statements. 2. Revenue Analysis Revenue Analysis 2007 2006Geographical analysis of revenue: £'000 £'000 United Kingdom 10,678 3,777 Europe 537 40 Rest of World 32 - 11,247 3,817 2007 2006Analysis by revenue stream: £'000 £'000 Acute Care 4,841 1,708 Aged Care 1,763 398 Devices 4,643 1,711 11,247 3,817 The Group has one main business segment. The above analysis by revenue stream isprovided for information purposes only. 3. Profit from operations Operating profit is after charging: Group 2007 2006 £'000 £'000Depreciation- owned asets 104 45Auditor's remunerationAudit services- Group 30 39- Company 10 15Non-audit services 75 51 Foreign exchange (gain) 0 (24) 4. Taxation The tax is assessed on the profit on ordinary activities for the year, is lowerthan at the standard rate of UK corporation tax of 30% (2006: 30%), as explainedbelow: 2007 2006 £'000 £'000 Profit of ordinary activities before taxation 538 (360) Profit of ordinary activities multiplied by 161 (108)30% Expenses not deductible for tax purposes 14 9 Depreciation in excess of capital allowances - - Utilisation of B/Fwd Loss Relief (175) - Carried forward - 99 Total Current Tax - - There is no tax charge for the year, due to availability of losses for off-setby group relief against other group company profits. As at 31 August 2007, thegroup had approximately £50,000 tax losses available, subject to agreement withHM Revenue & Customs. There are no material deferred tax balances as at 31 August 2007 and at 31 August 2006. 5. Profit per share GroupEarnings 2007 2006 £'000 £'000 Profit for the purpose of calculating basic profit per share 538 (360) Number of shares 2007 2006 Weighted average number of ordinary shares for the purposes of basic 265,314,440 171,314,367earnings per share Weighted average number of ordinary shares for the purposes of diluted 315,172,911 -earnings per share This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Intelliam Ai